Effects of γ-acetylenic GABA and γ-vinyl GABA on metrazol-activated, and kindled seizures

doi:10.1016/0091-3057(79)90133-3

Pharmacology Biochemistry and Behavior

Volume 11, Issue 3, September 1979, Pages 265-271

https://doi.org/10.1016/0091-3057(79)90133-3 Get rights and content

Abstract

Pretreatment of adult male Sprague-Dawley rats with a single dose of γ-vinyl GABA (GVG) (1200 mg/kg, IP) or γ-acetylenic GABA (GAG) (100 mg/kg, IP) did not affect the threshold of metrazol-activated generalized seizures, but increased their duration to the point of status epilepticus. In rats with epilepsy kindled by amygdaloid stimulation, a single dose of GVG (800 mg/kg, IP) and five subsequent daily administrations of GAG (80 mg/kg, IP) tended to reduce the motor manifestations of seizures leaving unaffected their electrographic pattern. The effects of GVG and GAG are attributed in part to decreased arousal. Practical implications of these findings are discussed.

References (40)

N.-E. Andén et al.
Baclofen and lithium in Huntington's Chorea
Lancet
(1973)
P.S. Arnold et al.
Effect of atropine, reserpine, 6-OHDA and handling on seizure development in the rat
Expl Neurol.
(1973)
M.E. Corcoran et al.
Potentiation of amygdaloid kindling and metrazol-induced seizures by 6-hydroxydopamine in rats
Expl Neurol.
(1974)
H. Corrodi et al.
Interaction between cholinergic and catecholaminergic neurones in rat brain
Brain Res.
(1972)
J. Engel et al.
Long-lasting depletion of dopamine in the rat amygdala induced by kindling stimulation
Brain Res.
(1977)
G.V. Goddard et al.
A permanent change in brain function resulting from daily electrical stimulation
Expl Neurol.
(1969)
K. Kuriyama et al.
Elevation of γ-aminobutyric acid in brain with amino-oxyacetic acid and susceptibility to convulsive seizures in mice: A quantitative re-evaluation
Biochem. Pharmac.
(1966)
B. Meldrum et al.
Drugs modifying dopaminergic activity and behaviour, the EEG and epilepsyin Papio papio
Eur. J. Pharmac.
(1975)
M.G. Palfreyman et al.
The effect of γ-acetylenic GABA, an enzyme-activated irreversible inhibitor of GABA-transaminase on dopamine pathways of the extrapyramidal and limbic systems
Eur. J. Pharmac.
(1978)
R.J. Racine
Modification of seizure activity by electrical stimulation. II. Motor seizure
Electroenceph. clin. Neurophysiol.
(1972)

E. Roberts et al.

A hypnotic and possible analgesic effect of imidazoleacetic acid in mice

Biochem. Pharmac.

(1966)

A. Scotti de Carolis et al.

Electroencephalographic and behavioral investigations on gabaergic drugs: muscimol, baclofen and sodium γ-hydroxybutyrate

Prog. Neuropsychopharmac.

(1978)

G.W. Sypert et al.

Single pyramidal-tract fiber analysis of neocortical propagated seizures with reference to inactivation responses

Expl Neurol.

(1974)

I.A. Sytinsky et al.

Neurochemical basis of the therapeutic effect of γ-aminobutyric acid and its derivatives

Prog. Neurobiol.

(1978)

R.A. Wise et al.

Effects of diazepam and phenobarbital on electrically-induced amygdaloid seizures and seizure development

Expl Neurol.

(1974)

N.E. Carlidge et al.

A comparison of baclofen and diazepam in the treatment of spasticity

J. Neurol. Sci.

(1974)

D. de Biolley et al.

Premiers résultats en clinique d'un nouvel anti-epileptique: Di-n-propyl acetate de sodium (DPA) spécialisé sous la marque Depakine

Acta neurol. belg.

(1969)

O.S. de Pinto et al.

A review of clinical trials with Lioresal

J. Engel et al.

Anatomical correlates of electrical and behavioral events related to amygdaloid kindling

Ann. Neurol.

(1978)

R.G. Feldman et al.

Baclofen for spasticity in multiple sclerosis

Neurology

(1978)

Cited by (61)

Vigabatrin for focal drug delivery in epilepsy: Bilateral microinfusion into the subthalamic nucleus is more effective than intranigral or systemic administration in a rat seizure model
2012, Neurobiology of Disease
Citation Excerpt :
Studies using systemic administration of vigabatrin also yielded apparently conflicting data. For instance, Myslobodsky et al. (1979), who injected PTZ (10–12 mg/kg i.p.) every 5 min starting 4 h after i.p. administration of vigabatrin (1200 mg/kg) in rats, reported a nonsignificant trend for increased PTZ threshold for generalized convulsions (from 56 to 70 mg/kg PTZ), but the duration of seizures was significantly increased after vigabatrin. We reported that vigabatrin blocked generalized convulsive seizures induced by PTZ (100 mg/kg s.c.) in mice with an ED50 of 940 mg/kg 6 h after i.p. administration (Löscher, 1980).
Vigabatrin is a rationally developed antiepileptic drug, which acts by increasing GABA levels in the brain by irreversibly inhibiting GABA degradation. However, its clinical use in epilepsy is restricted by severe side effects, including vision loss, which is thought to be a consequence of drug exposure of the retina and nonepileptic brain regions. Targeted delivery into brain regions involved in seizure generation and propagation would overcome this problem. Previous studies in rat models of seizures or epilepsy have shown that anticonvulsant effects can be achieved by bilateral microinjection of vigabatrin into the substantia nigra pars reticulata (SNr), a basal ganglia output structure that plays an important role in the modulation of seizures. In the present study, we compared the anticonvulsant efficacy of vigabatrin after systemic and intranigral administration in a rat model, in which seizure susceptibility can be determined by timed intravenous infusion of pentylenetetrazol (PTZ) before and after drug injection in individual animals. Furthermore, because the subthalamic nucleus (STN) plays a crucial role as a regulator of basal ganglia outflow by providing excitatory glutamatergic input into the two output nuclei of the basal ganglia, SNr and entopeduncular nucleus, we evaluated the effects of bilateral focal delivery of vigabatrin into the STN on PTZ seizure threshold. A significant increase in seizure threshold was observed following systemic (i.p.) administration of high (600 or 1200 mg/kg) doses of vigabatrin. Bilateral microinjection of vigabatrin (10 μg) into either the anterior or posterior SNr also increased seizure threshold, but less markedly than systemic treatment. In contrast, focal delivery into the STN increased seizure threshold more markedly than either intranigral or systemic administration of vigabatrin. Furthermore, focal inhibition of STN was not associated with the severe adverse effects associated with systemic treatment. The data demonstrate that vigabatrin is an interesting substance for focal drug delivery in epilepsy and may be advantageous compared to more commonly evaluated compounds such as muscimol.
Vigabatrin and tiagabine are pharmacologically different drugs. A pre-clinical study
1999, Seizure
In light of theirclosely related mechanisms of action, and preliminary clinical evidence suggesting that they possess similar efficacies, it has been anecdotally suggested that vigabatrin and tiagabine may prove to be therapeutically indistinguishable. As a result, we have conducted a preclinical comparison of their anticonvulsant profile and mechanism of action. Pentylenetetrazol and maximal electroshock seizures were employed to determine the experimental anticonvulsant profile. Mechanisms of action were investigated using assays of γ -aminobutyric acid (GABA), GABA-transaminase and glutamic acid decarboxylase in mouse brain and GABA uptake and GABA-transaminase in rat astrocyte cultures. Vigabatrin was without effect on either pentylenetetrazol- or maximal electroshock-induced seizures, whereas tiagabine increased the latency to pentylenetetrazol seizures and reduced the incidence of maximal electroshock seizures. In mouse brain assays, tiagabine was without effect, while vigabatrin increased GABA concentrations and reduced GABA-transaminase and glutamic acid decarboxylase activities. In cortical astrocyte cultures, vigabatrin reduced the activities of both GABA uptake and GABA-transaminase, whereas tiagabine blocked GABA uptake alone. These results suggest that vigabatrin and tiagabine have differing efficacy in experimental seizure models and distinct neurochemical effects. It is possible, then, that these drugs will have different spectra of activity and toxicity profiles in human epilepsy.
Potentiation effects in the dentate gyrus of pentylenetetrazol-kindled rats
1996, Physiology and Behavior
The study examines changes in the function of perforant pathway dentate granule cell synapses after pentylenetetrazol (PTZ) kindling. Field potentials evoked in the dentate area by test stimuli to the perforant pathway were recorded in freely moving rats at different times after injection of PTZ. In fully kindled animals, but not in sham-kindled controls, subconvulsive test doses of PTZ induced long-lasting potentiation of the population spike. Also, potentiation was not induced in naive controls injected with equieffective doses of the convulsant. The slope function of the field EPSP was depressed 90–120 min after PTZ administration, in both kindled and control animals, indicating that this was an effect of acute-injected PTZ. Later on, only in kindled animals that showed seizure stages 4 or 5 did it increase in parallel with the population spike potentiation. Finally, when compared to controls the kindled animals showed a greater pop spike potentiation induced by moderate tetanization of the perforant pathway. The model offers the possibility of differentiating between acute effects of the convulsant drug and kindling-related changes in neuronal plasticity.
Effects of GABA<inf>A</inf> receptors activation on brain glucose metabolism in normal subjects and temporal lobe epilepsy (TLE) patients. A positron emission tomography (PET) study Part II: The focal hypometabolism is reactive to GABA<inf>A</inf> agonist administration in TLE
1994, Epilepsy Research
Positron emission tomography (PET) using [¹⁸F]fluorodeoxyglucose (FDG) was used to study the metabolic response of focal hypometabolism to the administration of a specific GABA_A agonist (4, 5, 6, 7-tetrahydroisoxazolo[5, 4-c]pyridin-3-ol), THIP, in six temporal lobe epilepsy (TLE) patients. After THIP injection, the increase of glucose metabolism in the hypometabolic focus was larger than the mean increase reported in the whole brain (Part I;Epilepsy Res., 19 (1994) 45–54). Within the hypometabolic focus, this increase was significantly higher in regions with the lowest basal metabolic level. This metabolic response in the hypometabolic focus, observed in the absence of any epileptic discharge during FDG accumulation and PET data acquisition, suggests that GABA_A receptors are up-regulated or, at least, preserved in TLE.
Effect of nootropic Solcoseryl® on kainic acid-induced excitotoxic brain injury
1993, Pharmacology, Biochemistry and Behavior
Solcoseryl® (S) has been shown to provide significant cytoprotection in a variety of models of cerebral hypoxia. In the present study, we quantified the epileptiform effects caused by kainic acid administered into the pontine reticular formation of rats and their response to S pretreatment. Compared to saline, the agent appeared to significantly reduce the mortality of rats in the course of status epilepticus. However, S-pretreated rats manifested an increased incidence of behavioral seizures. This untoward effect is attributed to the fact that S improves the functional potential of injured tissue and retards the period of metabolic exhaustion at a time when neuronal activity should be minimized.
Development of tolerance to the anticonvulsant effect of vigabatrin in amygdala-kindled rats
1992, European Journal of Pharmacology
The anticonvulsant, adverse and biochemical effects of the novel antiepileptic drug vigabatrin (γ-vinyl GABA), which increases GABA (γ-aminobutyric acid) levels by inhibition of the GABA degrading enzyme GABA aminotransferase, were examined in amygdala-kindled rats after acute and chronic administration. Vigabatrin proved to be a potent anticonvulsant drug at acute doses (100–200 mg/kg), but during chronic administration, the anticonvulsant activity of the treatment was lost already in the second week of treatment. Tolerance also developed to the adverse effects, i.e. hypothermia, sedation and motor impairment. Determination of vigabatrin in plasma indicated that tolerance was not due to declining drug levels. Furthermore, determination of endogenous amino acids in plasma showed that GABA levels were highly elevated throughout the period of treatment, although the extent of GABA accumulation decreased in the second week. After cessation of chronic treatment with vigabatrin, there was no clear indication of withdrawal symptoms, except a prolonged seizure of afterdischarge duration in experiments with 100 mg/kg per day. The data suggest that chronic treatment with vigabatrin may be associated with a loss of anticonvulsant efficacy, at least when the drug is given as monotherapy.

View all citing articles on Scopus

¹: Permanent address: Psychobiology Research Unit, Department of Psychology, Tel-Aviv University, Tel-Aviv, Israel.

View full text

Effects of γ-acetylenic GABA and γ-vinyl GABA on metrazol-activated, and kindled seizures

Abstract

Lancet

Expl Neurol.

Expl Neurol.

Brain Res.

Brain Res.

Expl Neurol.

Biochem. Pharmac.

Eur. J. Pharmac.

Eur. J. Pharmac.

Electroenceph. clin. Neurophysiol.

Biochem. Pharmac.

Prog. Neuropsychopharmac.

Expl Neurol.

Prog. Neurobiol.

Expl Neurol.

A comparison of baclofen and diazepam in the treatment of spasticity

J. Neurol. Sci.

Premiers résultats en clinique d'un nouvel anti-epileptique: Di-n-propyl acetate de sodium (DPA) spécialisé sous la marque Depakine

Acta neurol. belg.

A review of clinical trials with Lioresal

Anatomical correlates of electrical and behavioral events related to amygdaloid kindling

Ann. Neurol.

Baclofen for spasticity in multiple sclerosis

Neurology